Mounjaro and Zepbound are likely to be Eli Lilly's top two products in the very near future.For a top drugmaker like Eli Lilly (LLY -1.01%), developing new drugs is key to ensuring that its business continues to grow. Patents don't last forever, so continuing to innovate is the only surefire way to be successful and remain a top company in the healthcare industry.In the past couple of years, the company has obtained approvals for multiple new products, including Mounjaro for diabetes, Zepbound for weight lo ...